.Competing passions.R.S., M.S., H.G. and A.A.R. are organizers of the 1M1M campaign. H.G. and A.A.R. are board of supervisors participants as well as R.S., M.S. and A.A.R. are members of the clinical consultatory board of N1C. A.A.R. reveals work through LUMC, which possesses patents on exon-skipping modern technology, several of which has been actually licensed to BioMarin and subsequently sublicensed to Sarepta. As co-inventor of a few of these patents, A.A.R. was actually qualified to a portion of aristocracies. A.A.R. better discloses acting as consultant for PTC Therapeutics, Sarepta Therapeutics, Regenxbio, Dyne Rehabs, Lilly, BioMarin Pharmaceuticals Inc., Eisai, Entrada, Takeda, Splicesense, Galapagos, Sapreme, Italfarmaco and also Astra Zeneca. Before 5 years, A.A.R. also did ad hoc speaking to for Alpha Anomeric. A.A.R. also mentions subscription of the scientific boards of advisers of Eisai, Hybridize Therapeutics, Silence Therapeutics, Sarepta Rehabs, Sapreme and Mitorx. Before 5 years, A.A.R. was actually additionally a medical board of advisers member for ProQR. Commission for A.A.R. u00e2 s consulting as well as advising tasks is spent to LUMC. Previously 5 years, LUMC likewise got speaker honoraria from PTC Therapies, Alnylam Netherlands, Italfarmaco and also Pfizer and cashing for deal research coming from Sapreme, Eisai, Galapagos, Synaffix as well as Alpha Anomeric. Venture funding is actually gotten from Sarepta Rehabs as well as Entrada by means of unregulated gives. H.G. possesses nothing at all to reveal in connection with the subjects covered in this document. In the past 5 years, he has additionally obtained working as a consultant honoraria coming from UCB. M.S. obtained consultancy honoraria coming from Ionis, UCB, Prevail, Orphazyme, Biogen, Servier, Reata, GenOrph, AviadoBio, Biohaven, Zevra, Lilly as well as Solaxa over the last 5 years, all unconnected to the here and now document. R.S. has absolutely nothing to divulge in regard to the topics dealt with in this composition. She has received speaker and/or consultancy gratuity or sponsoring payments coming from Abbvie, Bial, STADA as well as Everpharma over the last 5 years.